Effect of epoxide hydrolase polymorphisms on chromosome aberrations and risk for lung cancer

Cancer Genetics and Cytogenetics

Volumn 145, Issue 2, 2003, Pages 97-102

  Cajas Salazar, Nohelia ^a,b   Au, William W ^a   Zwischenberger, Joseph B ^c   Sierra Torres, Carlos H ^a,b   Salama, Salama A ^a,d   Alpard, Scott K ^c   Tyring, Stephen K ^c  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSIDAD DEL CAUCA   (Colombia)

^c University of Texas Medical Branch School of Medicine   (United States)

^d Al Azhar University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

EPOXIDE HYDROLASE;

ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CHROMOSOME ABERRATION; CIGARETTE SMOKING; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; EXON; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; STATISTICAL SIGNIFICANCE;

NICOTIANA TABACUM;

EID: 0043165103     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(03)00058-X     Document Type: Article

References (46)

1. National Cancer Institute. SEER Cancer Statistics Review, 1973-1998. 2001;National Institutes of Health, Bethesda, MD.
2. Warwick A., Sarhanis P., Redman C., Pemble S., Taylor J.B., Ketterer B., Jones P., Alldersea J., Gilford J., Yengi L. Theta class glutathione S-transferase GSTT1 genotypes and susceptibility to cervical neoplasia: interactions with GSTM1, CYP2D6 and smoking. Carcinogenesis. 15:1994;2841-2845.
3. Shopland D.R. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ Health Perspect. 103:(Suppl 8):1995;131-142.
4. Bergen A.W., Caporaso N. Cigarette smoking. J Natl Cancer Inst. 91:1999;1365-1375.
5. Giovino G.A., Schooley M.W., Zhu B.P., Chrismon J.H., Tomar S.L., Peddicord J.P., Merritt R.K., Husten C.G., Eriksen M.P. Surveillance for selected tobacco-use behaviors-United States, 1900-1994. Mor Mortal Wkly Rep CDC Surveill Summ. 43:1994;1-43.
6. Hirvonen A. Genetic factors in individual responses to environmental exposures. J Occup Environ Med. 37:1995;37-43.
7. d'Errico A., Malats N., Vineis P., Boffetta P. Review of studies of selected metabolic polymorphisms and cancer. IARC Sci Publ. 23:1999;323-393.
8. Omiecinski C.J., Hassett C., Hosagrahara V. Epoxide hydrolasepolymorphism and role in toxicology. Toxicol Lett. 112-113:2000;365-370.
9. Guengerich F.P. Epoxide hydrolase: properties and metabolic roles. Reviews Biochem Toxicol. 4:1982;5-30.
10. Seidegard J., DePierre J.W. Microsomal epoxide hydrolase. Properties, regulation and function. Biochim Biophys Acta. 695:1983;251-270.
11. Oesch F. Antimutagenesis by shift in monooxygenase isoenzymes and induction of epoxide hydrolase. Mutat Res. 202:1988;335-342.
12. Wang P., Meijer J., Guengerich F.P. Purification of human liver cytosolic epoxide hydrolase and comparison to the microsomal enzyme. Biochemistry. 21:1982;5769-5776.
13. Omiecinski C.J., Aicher L., Holubkov R., Checkoway H. Human peripheral lymphocytes as indicators of microsomal epoxide hydrolase activity in liver and lung. Pharmacogenetics. 3:1993;150-158.
14. Hassett C., Aicher L., Sidhu J.S., Omiecinski C.J. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. [published erratum appears in Hum Mol Genet 1994;3:1214] Hum Mol Genet. 3:1994;421-428.
15. Hassett C., Lin J., Carty C.L., Laurenzana E.M., Omiecinski C.J. Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. Arch Biochem Biophys. 337:1997;275-283.
16. Gaedigk A., Spielberg S.P., Grant D.M. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics. 4:1994;142-153.
17. Smith C.A., Harrison D.J. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. [see comments] Lancet. 350:1997;630-633.
18. Benhamou S., Reinikainen M., Bouchardy C., Dayer P., Hirvonen A. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res. 58:1998;5291-5293.
19. Persson I., Johansson I., Lou Y.C., Yue Q.Y., Duan L.S., Bertilsson L., Ingelman-Sundberg M. Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. Int J Cancer. 81:1999;325-329.
20. Lin P., Wang S.L., Wang H.J., Chen K.W., Lee H.S., Tsai K.J., Chen C.Y., Lee H. Association of CYP1A1 and microsomal epoxide hydrolase polymorphisms with lung squamous cell carcinoma. Br J Cancer. 82:2000;852-857.
21. London S.J., Smart J., Daly A.K. Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County. Lung Cancer. 28:2000;147-155.
22. Zhou W., Thurston S.W., Liu G., Xu L.L., Miller D.P., Wain J.C., Lynch T.J., Su L., Christiani D.C. The interaction between microsomal epoxide hydrolase polymorphisms and cumulative cigarette smoking in different histological subtypes of lung cancer. Cancer Epidemiol Biomarkers Prev. 10:2001;461-466.
23. Wu X., Gwyn K., Amos C.I., Makan N., Hong W.K., Spitz M.R. The association of microsomal epoxide hydrolase polymorphisms and lung cancer risk in African-Americans and Mexican-Americans. Carcinogenesis. 22:2001;923-928.
24. To-Figueras J., Gene M., Gomez-Catalan J., Pique E., Borrego N., Corbella J. Lung cancer susceptibility in relation to combined polymorphisms of microsomal epoxide hydrolase and glutathione S-transferase P1. Cancer Lett. 173:2001;155-162.
25. Zhao H., Spitz M.R., Gwyn K.M., Wu X. Microsomal epoxide hydrolase polymorphisms and lung cancer risk in non-Hispanic whites. Mol Carcinog. 33:2002;99-104.
26. Au W.W., Walker D.M., Ward J.B.J., Whorton E., Legator M.S., Singh V. Factors contributing to chromosome damage in lymphocytes of cigarette smokers. Mutat Res. 260:1991;137-144.
27. Conforti-Froes N., el-Zein R., Abdel-Rahman S.Z., Zwischenberger J.B., Au W.W. Predisposing genes and increased chromosome aberrations in lung cancer cigarette smokers. Mutat Res. 379:1997;53-59.
28. Au W.W., Cajas-Salazar N., Salama S. Factors contributing to discrepancies in population monitoring studies. Mutat Res. 400:1998;467-478.
29. Hansen M.F., Cavenee W.K. Genetics of cancer predisposition. Cancer Res. 47:1987;5518-5527.
30. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
31. Solomon E., Borrow J., Goddard A.D. Chromosome aberrations and cancer. Science. 254:1991;1153-1160.
32. Bonassi S., Abbondandolo A., Camurri L., Dal Pra L., De Ferrari M., Degrassi F., Forni A., Lamberti L., Lando C., Padovani P. Are chromosome aberrations in circulating lymphocytes predictive of future cancer onset in humans? Preliminary results of an Italian cohort study. Cancer Genet Cytogenet. 79:1995;133-135.
33. Hagmar L., Bonassi S., Stromberg U., Brogger A., Knudsen L.E., Norppa H., Reuterwall C. Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Cancer Res. 58:1998;4117-4121.
34. el-Zein R., Conforti-Froes N., Au W.W. Interactions between genetic predisposition and environmental toxicants for development of lung cancer. Environ Mol Mutagen. 30:1997;196-204.
35. el-Zein R., Zwischenberger J.B., Abdel-Rahman S.Z., Sankar A.B., Au W.W. Polymorphism of metabolizing genes and lung cancer histology: prevalence of CYP2E1 in adenocarcinoma. Cancer Lett. 112:1997;71-78.
36. Ellis N.A., German J. Molecular genetics of Bloom's syndrome. Hum Mol Genet. 5:1996;1457-1463.
37. Eastmond D.A., Rupa D.S., Hasegawa L.S. Detection of hyperdiploidy and chromosome breakage in interphase human lymphocytes following exposure to the benzene metabolite hydroquinone using multicolor fluorescence in situ hybridization with DNA probes. Mutat Res. 322:1994;9-20.
38. Au W.W., Sierra-Torres C.H., Cajas-Salazar N., Salama S.A. Inheritance of polymorphic metabolizing genes on environmental disease and quality of life. Mutat Res. 428:1999;131-140.
39. Au W.W., Sierra-Torres C.H., Cajas-Salazar N., Shipp B.K., Legator M.S. Cytogenetic effects from exposure to mixed pesticides and the influence from genetic susceptibility. Environ Health Perspect. 107:1999;501-505.
40. Salama S.A., Sierra-Torres C.H., Oh H.Y., Hamada F.A., Au W.W. Variant metabolizing gene alleles determine the genotoxicity of benzo[a]pyrene. Environ Mol Mutagen. 37:1901;17-26.
41. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:1988;1215.
42. Lancaster J.M., Brownlee H.A., Bell D.A., Futreal P.A., Marks J.R., Berchuck A., Wiseman R.W., Taylor J.A. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog. 17:1996;160-162.
43. Rothman N., Wacholder S., Caporaso N.E., Garcia-Closas M., Buetow K., Fraumeni J.F. Jr. The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim Biophys Acta. 1471:2001;C1-C10.
44. Bonassi S., Fontana V., Ceppi M., Barale R., Biggeri A. Analysis of correlated data in human biomonitoring studies. The case of high sister chromatid exchange frequency cells. Mutat Res. 438:1999;13-21.
45. Jourenkova-Mironova N., Mitrunen K., Bouchardy C., Dayer P., Benhamou S., Hirvonen A. High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers. Cancer Res. 60:2000;534-536.
46. Tsutsumi M., Wang J.S., Takase S., Takada A. Hepatic messenger RNA contents of cytochrome P4502E1 in patients with different P4502E1 genotypes. Alcohol Alcohol. 29:(Suppl 1):1994;29-32.